Senseonics Holdings Inc (SENS)

NASDAQHealth CareMedical - DevicesSnapshot 2026-10-23

$7.51+1.49%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Senseonics Holdings Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	21.85M
EPS	—	-0.458
FY 2026 · Annual
Revenue	$62M–$66M	64.24M
EPS	—	-2.283
FY 2027 · Annual
Revenue	—	99.98M
EPS	—	-1.926

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Gross margin improves to about 56.5% in FY26	Gross margin is improving to about 56.5% in 2026.	Intact	Gross margin falls below 55% in FY26	Gross margin: 59.1% FY2026-Q2; GAAP. Published target: >= 55% gross margin in FY26. Target period ends 2026-12-31; this observation covers 2026-Q2. Source published Aug 6, 202659.096872 percent · calculatedSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 60fb8a8c-698c-4bdb-a41e-c1ce3e46a22c. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Growth supported by strategic acquisitions	The company is expanding through acquisitions to boost growth.	Intact	No meaningful acquisitions or failed integration in 2026	Acquisition closed Jun 2026 vs 2026 target Form 8-K confirms closing of asset purchase agreements with Ascensia Diabetes Care in June 2026. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Operating income improves from -$31.8M in 2026-Q1	A primary condition in Senseonics Holdings Inc's published investment case. The stated target is Operating loss narrows from -$31.8M in 2026-Q1 over next 4 quarters.	Broken	Operating loss worsens beyond -$31.8M in next 4 quarters	Operating income: $-35.988M FY2026-Q2; GAAP. Published target: Operating loss narrows from -$31.8M in 2026-Q1 over next 4 quarters. Target period is not explicitly aligned with this observation. Source published Aug 6, 2026-35,988,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 60fb8a8c-698c-4bdb-a41e-c1ce3e46a22c. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Revenue grows to about $62M in FY26	A primary condition in Senseonics Holdings Inc's published investment case. The stated target is >= $60M revenue in FY26.	Intact	Revenue falls below $60M in FY26	Revenue: $14.483M FY2026-Q2; GAAP. Published target: >= $60M revenue in FY26. Target period ends 2026-12-31; this observation covers 2026-Q2. Source published Aug 6, 202614,483,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 60fb8a8c-698c-4bdb-a41e-c1ce3e46a22c. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-1.93

$-2.15 → $-1.93 · observed estimates

FY2027 revenue$0.10B

$0.10B → $0.10B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-2.15	$97,927,829	5 / 6
2026-07-25	$-2.15	$97,927,829	5 / 6
2026-07-26	$-2.19	$97,938,570	6 / 7
2026-07-27	$-2.15	$97,922,000	5 / 6
2026-07-28	$-2.19	$97,938,570	6 / 7
2026-07-29	$-2.15	$97,922,000	5 / 6
2026-07-30	$-2.19	$97,938,570	6 / 7
2026-07-31	$-2.15	$97,922,000	5 / 6
2026-08-01	$-2.15	$97,922,000	5 / 6
2026-08-02	$-2.19	$97,938,570	6 / 7
2026-08-03	$-2.19	$97,938,570	6 / 7
2026-08-04	$-2.19	$97,938,570	6 / 7
2026-08-05	$-2.19	$97,938,570	6 / 7
2026-08-06	$-2.19	$97,938,570	6 / 7
2026-08-08	$-2.21	$98,267,140	5 / 7
2026-08-09	$-2.21	$98,267,140	5 / 7
2026-08-10	$-2.21	$98,267,140	5 / 7
2026-08-12	$-2.15	$97,922,000	5 / 6
2026-08-13	$-2.15	$97,922,000	5 / 6
2026-08-14	$-2.15	$97,922,000	5 / 6
2026-08-15	$-2.15	$97,922,000	5 / 6
2026-08-16	$-2.15	$97,922,000	5 / 6
2026-08-17	$-2.15	$97,922,000	5 / 6
2026-08-18	$-2.15	$97,922,000	5 / 6
2026-08-19	$-2.15	$97,922,000	5 / 6
2026-08-20	$-1.93	$99,975,714	5 / 6
2026-08-21	$-1.93	$99,975,714	5 / 6
2026-08-22	$-1.93	$99,975,714	5 / 6
2026-08-23	$-1.93	$99,975,714	5 / 6
2026-08-24	$-1.93	$99,975,714	5 / 6
2026-08-25	$-1.93	$99,975,714	5 / 6
2026-08-26	$-1.93	$99,975,714	5 / 6
2026-08-27	$-1.93	$99,975,714	5 / 6
2026-08-28	$-1.93	$99,975,714	5 / 6
2026-08-29	$-1.93	$99,975,714	5 / 6
2026-08-30	$-1.93	$99,975,714	5 / 6
2026-08-31	$-1.93	$99,975,714	5 / 6
2026-09-01	$-1.93	$99,975,714	5 / 6
2026-09-02	$-1.93	$99,975,714	5 / 6
2026-09-03	$-1.93	$99,975,714	5 / 6
2026-09-04	$-1.93	$99,975,714	5 / 6
2026-09-05	$-1.93	$99,975,714	5 / 6
2026-09-06	$-1.93	$99,975,714	5 / 6
2026-09-07	$-1.93	$99,975,714	5 / 6
2026-09-08	$-1.93	$99,975,714	5 / 6
2026-09-09	$-1.93	$99,975,714	5 / 6
2026-09-10	$-1.93	$99,975,714	5 / 6
2026-09-11	$-1.93	$99,975,714	5 / 6
2026-09-12	$-1.93	$99,975,714	5 / 6
2026-09-13	$-1.93	$99,975,714	5 / 6
2026-09-14	$-1.93	$99,975,714	5 / 6
2026-09-15	$-1.93	$99,975,714	5 / 6
2026-09-16	$-1.93	$99,975,714	5 / 6
2026-09-17	$-1.93	$99,975,714	5 / 6
2026-09-18	$-1.93	$99,975,714	5 / 6
2026-09-19	$-1.93	$99,975,714	5 / 6
2026-09-20	$-1.93	$99,975,714	5 / 6
2026-09-21	$-1.93	$99,975,714	5 / 6
2026-09-22	$-1.93	$99,975,714	5 / 6
2026-09-23	$-1.93	$99,975,714	5 / 6
2026-09-24	$-1.93	$99,975,714	5 / 6
2026-09-25	$-1.93	$99,975,714	5 / 6
2026-09-26	$-1.93	$99,975,714	5 / 6
2026-09-27	$-1.93	$99,975,714	5 / 6
2026-09-28	$-1.93	$99,975,714	5 / 6
2026-09-29	$-1.93	$99,975,714	5 / 6
2026-09-30	$-1.93	$99,975,714	5 / 6
2026-10-01	$-1.91	$99,975,714	5 / 6
2026-10-02	$-1.91	$99,975,714	5 / 6
2026-10-03	$-1.91	$99,975,714	5 / 6
2026-10-04	$-1.91	$99,975,714	5 / 6
2026-10-05	$-1.91	$99,975,714	5 / 6
2026-10-06	$-1.91	$99,975,714	5 / 6
2026-10-07	$-1.93	$99,975,714	5 / 6
2026-10-08	$-1.93	$99,975,714	6 / 6
2026-10-09	$-1.93	$99,975,714	6 / 6
2026-10-10	$-1.93	$99,975,714	6 / 6
2026-10-11	$-1.93	$99,975,714	6 / 6
2026-10-12	$-1.93	$99,975,714	6 / 6
2026-10-13	$-1.93	$99,978,971	6 / 6
2026-10-14	$-1.93	$99,981,643	6 / 6
2026-10-15	$-1.93	$99,981,643	6 / 6
2026-10-16	$-1.93	$99,981,643	6 / 6
2026-10-17	$-1.93	$99,981,643	6 / 6
2026-10-18	$-1.93	$99,981,643	6 / 6
2026-10-19	$-1.93	$99,981,643	6 / 6
2026-10-20	$-1.93	$99,981,643	6 / 6
2026-10-21	$-1.93	$99,981,643	6 / 6
2026-10-22	$-1.93	$99,981,643	6 / 6
2026-10-23	$-1.93	$99,981,643	6 / 6
2026-10-24	$-1.93	$99,981,643	6 / 6

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	5	2	1
2026-06-01	4	2	1
2026-07-01	4	2	1
2026-08-01	4	2	1
2026-09-01	4	2	1
2026-10-01	4	3	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 4 Buy / Strong Buy · 3 Hold · 1 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

BarclaysOct 6

$10.00New observation · no comparable prior

$0$5.50$11.00

0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Gross margin improves to about 56.5% in FY26Gross margin: 59.1%
Operating income improves from -$31.8M in 2026-Q1Published status: Broken
Revenue grows to about $62M in FY26Revenue: $14.483M

Next proof point

Nov 9, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.6%Typical daily move · historical

Downside history

-41.8%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Senseonics Holdings Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative growth business, with revenue growth and improving margins supporting the long-term thesis. Management is delivering on stated priorities, but the company remains loss-making and recent financial performance is weak.

What's priced into Senseonics Holdings Inc

The valuation evidence points to a premium versus peers, with optionality as the main reason for the difference. The expectations gap is negative, but model confidence is low, so the valuation read is uncertain. The evidence does not show strong fragility in what is priced in.

What the fundamentals likely do

Near term, revenue growth and gross-margin progress are positive, and management has raised full-year 2026 gross-margin guidance. However, SENS has recently missed earnings more than once, and the next report carries an elevated miss risk. Equity and debt financing have strengthened the balance sheet to support commercial and product work, but the business remains loss-making.

What Senseonics Holdings Inc hinges on

The multi-year thesis depends on continued revenue growth, margin improvement, and execution of commercial and product plans. A reversal of recently raised guidance would damage credibility, while further earnings misses could keep performance weak. Strong results and guidance from healthcare peers could support the sector backdrop, though a weakening jobs trend may weigh on cyclical healthcare names.